Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Video
The Aftermath of Hepatitis C Drugs on Specialty Spending
Author(s):
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Related Videos
Related Content
